Home » Newsletters » BioWorld Science

BioWorld Science

July 1, 2015

View Archived Issues

Yakult Honsha begins Japanese phase I study of resminostat for pancreatic or biliary tract cancer

BARDA exercises additional contract funding for AEOL-10150

[18F]PTV-F1 PET: imaging liver OATP transporter

New gene therapy shows safety and efficacy for the treatment of ADA deficiency

Invion completes dosing in phase II trial of oral INV-102 in smoking cessation

Cynapsus initiates phase III trial of AP-130277 for Parkinson's disease

Phase II trial of SYN-010 begins in irritable bowel syndrome with constipation

Phase III study of Emend meets endpoint in chemotherapy-induced nausea and vomiting

FibroGen receives license payment from AstraZeneca for roxadustat

Celgene and Juno establish 10-year global immunotherapy collaboration

Clinical activity seen with AM-0010 in first-in-human trial

McMaster University develops a novel model of cancer-induced depression

Stelara receives European approval for adolescents with moderate to severe psoriasis

Vitae initiates phase I study of VTP-43742 for autoimmune disorders

New biomarker identified for anti-EGFR therapy prognosis

Combination of durvalumab with dabrafenib and/or trametinib

Merck & Co. discloses orexin OX2 receptor antagonists

Daiichi Sankyo patents LCAT activators

Bayer Schering Pharma introduces sGC activators

JST patents Abeta aggregation inhibitors

Medshine Discovery presents anti-RSV agents

Telesta Therapeutics submits BLA to the FDA for MCNA

Bayer Yakuhin launches Gadovist intravenous injection 1.0 mol/L in Japan

MJFF and MSPRF Parkinson's research foundations to merge

FDA awards QIDP designation to Innocoll's gentamicin collagen matrix for diabetic foot infections

Expanded indication for Adenuric in Europe

FDA grants fast track status to Aerucin for hospital-acquired and ventilator-associated pneumonia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...